New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
15:30 EDTWFT, TSCO, SKX, CTXS, NXPI, ETFC, ORLY, CCI, FB, AVB, GILD, T, TRIP, ILMN, QCOMNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include AT&T (T), consensus 63c; Facebook (FB), consensus 32c; QUALCOMM (QCOM), consensus $1.22; Gilead (GILD), consensus $1.79; Crown Castle (CCI), consensus $1.01; Illumina (ILMN), consensus 51c; Avalonbay (AVB), consensus $1.66; O'Reilly Automotive (ORLY), consensus $1.85; TripAdvisor (TRIP), consensus 61c; Citrix (CTXS), consensus 61c; Tractor Supply (TSCO), consensus 95c; E*TRADE (ETFC), consensus 23c; Skechers (SKX), consensus 40c; Weatherford International (WFT), consensus 21c; NXP Semiconductors (NXPI), consensus $1.06
News For T;FB;QCOM;GILD;CCI;ILMN;AVB;ORLY;TRIP;CTXS;TSCO;ETFC;SKX;WFT;NXPI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | all recent news | >>
July 16, 2015
09:35 EDTFBActive equity options trading on open
Subscribe for More Information
09:22 EDTGILDBristol-Myers says EU approves Evotaz for treatment of HIV-1 infection in adults
Subscribe for More Information
08:53 EDTFBFacebook to buy Pebbles for about $60M, WSJ reports
Subscribe for More Information
08:18 EDTQCOMSeveral stocks attractive following Intel results, says JMP Securities
For investors looking to take advantage of the sentiment shift the Intel (INTC) results could mean for the group and stronger demand due to seasonality and the Windows 10 launch, JMP Securities recommends Nvidia (NVDA) and Micron (MU). The firm says that both stocks have more attractive valuations and "more strategic roadmaps" than Intel. It also recommends Apple (AAPL) and Qualcomm (QCOM) as more attractive and secure dividend growth plays.
08:14 EDTFBFacebook faces foreign exchange headwinds in Q2, says Brean Capital
Subscribe for More Information
06:33 EDTILMNIllumina launches large-scale genome sequencing solution SeqLab
Subscribe for More Information
06:08 EDTILMNPiper says buy Illumina on weakness despite mixed checks
Subscribe for More Information
05:51 EDTQCOMEuropean Commission confirms two investigations against Qualcomm
Subscribe for More Information
05:22 EDTQCOMQualcomm issues statement on European Commission announcement
Qualcomm provided the following statement: "We were informed that the European Commission has taken the procedural step of 'initiating proceedings' against Qualcomm with regard to the two ongoing investigations into Qualcomm's sale of chipsets for mobile devices. This step allows investigators to gather additional facts, but it represents neither an expression by the Commission on the merits of the case nor an accusation against the company. While we were disappointed to hear this, we have been cooperating and will continue to cooperate with the Commission, and we continue to believe that any concerns are without merit."
July 15, 2015
16:00 EDTFBOptions Update; July 15, 2015
Subscribe for More Information
10:01 EDTQCOMOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:32 EDTFBActive equity options trading on open
Active equity options trading on open: AAPL FB BAC RCPT MU YUM NFLX CELG
09:18 EDTFBAdobe's Flash disabled by Google due to security worries, WSJ says
Just days after Facebook's (FB) top security executive called on Adobe (ADBE) to discontinue its Flash animation player, Google’s (GOOG) Chrome and Mozilla’s Firefox browsers blocked old versions of the software on Tuesday after reports that hackers were using a security flaw to infiltrate computers, reported The Wall Street Journal's "Digits" blog. Firefox and Chrome will allow Flash to run again if it is updated with the patch Adobe released Tuesday morning, the report noted. Reference Link
08:33 EDTFBFacebook target raised to $110 at Morgan Stanley on mobile ad strength
Morgan Stanley raised 2015 and 2016 revenue estimates for Facebook and increased its price target on the shares to $110 due to scale and improving products. The firm's mobile ad checks indicate Facebook is still the mobile industry leader, has low pricing and high ad ROI, and continues to pull in a larger share of ad budgets and ad dollars per MAU. Morgan Stanley has an Overweight rating on shares of the social network owner, which closed yesterday at $89.68.
08:27 EDTFBAdobe says Google display ad strategy underperforms Facebook in Q2
In its "Digital Advertising & Social Intelligence Report" for Q2, Adobe (ADBE) wrote that Facebook's (FB) display ad changes doubled its click-through-rates, or CTRs, year-over-year in the quarter, while Google's (GOOG) display targeting changes reduced its number of ads seen by 22% compared to the prior year and its CTRs were up "only" 24% compared to the same period of last year. The report also contends that the "Mobilegeddon" fears regarding Google's changes to favor mobile friendly sites came true, noting that sites with low mobile engagement saw up to a 10% decrease in organic traffic after the changes were made by the search giant. Reference Link
07:58 EDTGILDAnalysts break down impact of $7.2B Receptos buyout
After Celgene (CELG) announced last night that the company has agreed to acquire Receptos (RCPT) for $232 per share in cash, or a total of about $7.2B net of cash acquired, research firms have chimed in with their opinions on how the proposed deal may impact others in the biotech space. Receptos key asset is Ozanimod, which is being studied in Phase III trials for relapsing multiple sclerosis and ulcerative colitis. DERIVATIVE CALLS: Piper Jaffray analyst Edward Tenthoff told investors that he views Celgene's deal for Receptos as good for Arena Pharmaceuticals (ARNA). The analyst notes that Arena's APD334 is already showing dose-dependent decreases in circulating lymphocyte counts and that the company will initiate Phase II studies in ulcerative colitis and Crohn's disease this year. Tenthoff reiterates an Overweight rating and $7.50 price target on Arena, which has a market capitalization around $1B and closed yesterday up 8c to $4.47. In its own note to investors this morning, Nomura said Celgene's deal could put downward pressure on Biogen's (BIIB) long-term multiple sclerosis estimates. Nomura's M. Ian Somaiya contended that one-year Phase II efficacy data for Ozanimod looked as good as Novartis’s (NVS) Gilenya and Biogen's Tecfidera’s Phase III at year 2. Somaiya also wondered if rival Gilead (GILD) could be "looking for something bigger" than Receptos for its own deal, telling investors that the firm views Incyte (INCY) as Gilead's most likely takeout target. Incyte's shares closed up $4.46 at $117.46 yesterday, giving the company a market cap of about $20B. RIVAL BID?: Wedbush analyst Liana Moussatos believes another bidder may seek to acquire Receptos, noting that she previously estimated Receptos could be valued at $348 per share, or about $10.9B, in a buyout. Moussatos noted that Celgene said it expects annual peak sales for Ozanimod to reach about $4B-$6B for RMS and UC, making its acquisition price of $7.2BN only a bit more than about 1X peak sales without accounting for other possible indications or the rest of its pipeline. Moussatos told investors she sees "plenty" of potential upside to justify a rival bidder stepping in and reiterated the firm's Outperform rating on Receptos shares. PRICE ACTION: In pre-market trading, Receptos rose 10% to $228.61 while Gilead gained 1.4% to about $119 per share.
06:52 EDTTFCC ruling on AT&T-DirecTV deal could come as soon as today, CTFN says
Subscribe for More Information
06:50 EDTQCOMQualcomm initiated with a Neutral at Mizuho
Subscribe for More Information
05:55 EDTQCOMQualcomm to push inexpensive mobile device market in 2015, DigiTimes reports
Subscribe for More Information
05:53 EDTQCOMTSMC cuts 28nm and 20nm prices by 5%-10%, DigiTimes reports
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use